Carol J. Wikstrand - Concepedia

Author

Carol J. Wikstrand

Also Known As

C J Wikstrand, C. J. WIKSTRAND, C. J. Wikstrand, C.J. Wikstrand, CAROL J. WIKSTRAND, Carol J Wikstrand, Carol J. WIKSTRAND, Carol J. Wikstrand, Carol Wikstrand, Cj Wikstrand

132

Publications

9.5K

Citations

H-Index

Concepts

All Affiliations

Duke Medical Center Duke University Hospital Duke University National Cancer Institute University of Gothenburg

About

Carol J. Wikstrand is an author at Duke Medical Center specializing in medicine, glioma, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	49	4.1K
2	Health Sciences	5	5	645
3	Social Sciences	2	2	109
4	Engineering	1	1	61
5	Natural Sciences	1	1	30

Carol J. Wikstrand

Publications

8.5K

Citations

H-Index

Page 1

	Year	Citations
Phase II Trial of Gefitinib in Recurrent Glioblastoma Jeremy N. Rich, David A. Reardon, Terry Peery, Journal of Clinical Oncology	2003	726
Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting John C. Sok, Francesca M Coppelli, Sufi M. Thomas, Clinical Cancer Research	2006	488
Heterogeneity of Genotypic and Phenotypic Characteristics of Fifteen Permanent Cell Lines Derived from Human Gliomas Darell D. Bigner, Sandra H. Bigner, Jan Pontén, Journal of Neuropathology & Experimental Neurology	1981	484
Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Carol J. Wikstrand, Laura P. Hale, Surinder K. Batra, PubMed Specific MabsSpecific Monoclonal AntibodiesCancer ImmunosurveillanceMalignant DiseaseMedicine	1995	470
Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Mario A. Bourdon, Carol J. Wikstrand, Heinz Furthmayr, PubMed Tumor InnervationImmunologyPathologyImmunophenotypingHigh-grade Gliomas	1983	375
Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Carol J. Wikstrand, Roger E. McLendon, Allan H. Friedman, PubMed ImmunologyPathologyDermatologyCell GrowthGlioma	1997	328
Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Surinder K. Batra, Shobha Castelino‐Prabhu, Carol J. Wikstrand, PubMed Nr6m CellsDevelopmental BiologyGliomaNr6w CellsMedicine	1995	286
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition Ranjit K. Goudar, Qing Shi, Mark D. Hjelmeland, Molecular Cancer Therapeutics Neuro-oncologyMammalian TargetGliomaMedicineReceptor Tyrosine Kinase	2005	244
Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors John H. Sampson, Gamal Akabani, Gary E. Archer, Journal of Neuro-Oncology	2003	237
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Amy B. Heimberger, Laura E. Crotty Alexander, Gary E. Archer, PubMed	2003	237

Page 1